Vision RT Launches Completely New Camera
Building the Foundation to the Future of SGRT

24 October 2021

London, United Kingdom

Vision RT, the leaders in Surface Guided Radiation Therapy (SGRT), unveiled their second new product this year - the Horizon Camera - at the American Society for Radiation Oncology (ASTRO) Annual Meeting this week in Chicago. The Horizon camera opens completely new possibilities for radiation therapy.

With nearly 2,000 systems, more than 5,000 camera units already in clinical use, and over 20 years’ experience in SGRT, Vision RT’s proprietary 3D cameras are trusted for their accuracy and effectiveness worldwide. The Horizon camera builds on the performance of previous AlignRT cameras through added functionality and capabilities that enable entirely new products.

Vision RT introduces its latest product, DoseRT™, showcased at this year’s ASTRO Annual Meeting. As the pioneer of SGRT, Vision RT now brings another world’s first – real-time patient monitoring and beam imaging, at the same time. DoseRT is born from combining the power of Cherenkov Imaging with BeamSite™ (DoseOptics LLC) and Vision RT’s newest camera system, Horizon.

According to a recent study¹, Cherenkov imaging, developed by DoseOptics and used at Dartmouth-Hitchcock hospital, identified key areas for delivery improvement in nearly 10% of the patients studied. DoseRT can detect these incidents in real-time and allow the treatment to be corrected.

Lesley Jarvis, MD, PhD, Department of Medicine, Section of Radiation Oncology, Geisel School of Medicine at Dartmouth and lead author on the study, said “One of the fundamental challenges of radiation therapy is treating without being able to see the beam. Our work has shown that even competent radiation oncology clinics can identify opportunities to improve their radiation delivery practice by monitoring every fraction with Cherenkov imaging. I’m also sure that we’ve just scratched the surface and believe it will be a key part to every clinic’s quality improvement program.”

The second application of Horizon images the entire surface of the patient to enable more accurate and effective radiation treatments. Initial results will be shared at the ASTRO Annual Meeting at a presentation by Minsong Cao, Clinical Professor and Associate Vice Chair of Radiation Oncology, UCLA. Some applications of this product are being developed in collaboration with RaySearch Laboratories.

Dr Ke Sheng, who is leading the project from the UCLA side, said “Our early clinical work suggests we can deliver something completely new, and highly valuable, to patients requiring more tightly targeted radiation treatment. With this product, conventional fears of collisions can be put aside, giving freedom to planners to choose a much wider array of treatment angles, and hopefully, therefore, superior dose distribution.”

Johan Löf, President and CEO at RaySearch Laboratories, said “Surface scanning is a great source of information that can be used together with sophisticated new planning methods to significantly improve the cancer treatment planning process as well as the treatment quality. We are very excited to be working with Vision RT on this project.”

Norman Smith, CEO of Vision RT, said “With our technology installed in around one-third of all treatment delivery systems in the USA, SGRT is clearly becoming the standard of care. And we’ve only just begun. Detecting surface dose and using the whole patient surface to deliver better dose distribution are innovations that will improve treatments for many patients everywhere as SGRT becomes the standard of care for every clinic in the world.”

Horizon cameras are already in routine clinical use in the UK.

Horizon cameras are not currently for sale in the USA. 510(k) pending (submitted August 2021). Applications mentioned using Horizon camera are work in progress and will require additional purchase. DoseRT is a trademark of Vision RT, BeamSite is a trademark of DoseOptics LLC. RaySearch and associated trademarks are the property of RaySearch Laboratories.

----ENDS----

About Vision RT
Vision RT defines the standard of care in Surface Guided Radiation Therapy (SGRT). With +80 granted patents and +50 pending, Vision RT continues to innovate in the radiation oncology space and is committed to making SGRT the standard of care for all patients, worldwide. There are more than 1,700 systems installed worldwide.
SGRT, pioneered by Vision RT, uses proprietary 3D stereo camera units to monitor a patient’s skin surface in real-time and compare it to the ideal position with sub-millimetric accuracy. This ensures that radiation is delivered only when a patient is correctly positioned, enhancing safety and comfort.

AlignRT SGRT from Vision RT is used by nine of the ten “Best Hospitals for Cancer” according to U.S. News and World Report.

Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 18,000 people, with a total revenue of more than $3 billion.

For more information:
- https://visionrt.com
- General: enquiries@visionrt.com
- Sales: sales@visionrt.com
- Vision RT media queries: Billy Cometti Bcometti@visionrt.com, Head of Communications

About DoseOptics
DoseOptics LLC was founded to improve the delivery of radiotherapy through Cherenkov imaging. With its recent FDA 510(k) clearance, DoseOptics has introduced BeamSite™, the world’s first camera system capable of imagining radiotherapy treatments and showing, in real-time, direct images of the treatment beam coincident with patient tissue. In clinical practice, BeamSite has identified ways to improve the quality of patient’s treatment.

DoseOptics LLC has established the foundation of its technology with the help from Dartmouth Engineering School and the Norris Cotton Cancer Center at Dartmouth Hitchcock Hospital leading to key patent awards and over 50 peer reviewed publications in Cherenkov imaging.

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation® treatment planning system (TPS) and the oncology information system (OIS) RayCare®. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand®, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

RaySearch software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

About RayStation
RayStation® is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one
control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.